New obesity drug candidate cagrilintide gets closer look in early trial
NCT ID NCT07605052
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This early-stage study will compare two different versions of the drug cagrilintide in 50 adults with overweight or obesity. Participants will receive injections of either version for several weeks, and researchers will measure how the drug builds up in the body. The goal is to see which version works better for future weight-loss treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cagrilintide
- What this could lead to
- If successful, this study could help select the best version of cagrilintide for future weight-loss treatments.
- What could go wrong
- This is an early Phase 1 trial with only 50 participants, focused on drug levels in the body, not weight loss. It is too early to know if it will lead to an effective treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion, Phoenix
Tempe, Arizona, 85283, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?